Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated Recombinant Human Growth Hormone in Prepubertal Short Stature Children with Different BMI
ChiCTR2500114064Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin in growth disorder (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Height standard deviation score. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on ChiCTR2500114064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114064.